Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Jul 28, 2013; 19(28): 4511-4519
Published online Jul 28, 2013. doi: 10.3748/wjg.v19.i28.4511
Published online Jul 28, 2013. doi: 10.3748/wjg.v19.i28.4511
Table 1 Patients’ characteristics n (%)
| Characteristics | Categories | Data |
| Age (yr) | Median (range) | 64 (35-81) |
| Gender | Male | 25 (54) |
| Female | 21 (46) | |
| Stage | Locally advanced | 5 (11) |
| Metastatic | 41 (89) | |
| ECOG PS | 0 | 10 (22) |
| 1 | 26 (56) | |
| 2 | 9 (20) | |
| 3 | 1 (2) | |
| Basal CA 19-9 (U/mL) | Median (range) | 897 (1-49, 483) |
| Interval between symptoms and treatment (wk) | Median (range) | 12 (2-179) |
| Clinical benefit | Evaluable | 33 (75) |
| Not evaluable | 13 (25) | |
| Follow-up (wk) | Median (range) | 21.5 (2-91) |
| Number of administrations | Median (range) | 9 (1-29) |
- Citation: Vaccaro V, Bria E, Sperduti I, Gelibter A, Moscetti L, Mansueto G, Ruggeri EM, Gamucci T, Cognetti F, Milella M. First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer. World J Gastroenterol 2013; 19(28): 4511-4519
- URL: https://www.wjgnet.com/1007-9327/full/v19/i28/4511.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i28.4511